Aglaris Limited (Aglaris) is developing innovative, automated cell culture platform technologies. Set up in 2014, Aglaris aims to solve the bottleneck in cell manufacturing, currently inhibiting the wider application of cell-based therapies within regenerative medicine.

Aglaris has a clear aspiration to provide an enabling technology platform to make cell therapy a reality. To meet the needs of cell therapies, cell production needs to be more affordable and technically competitive. Aglaris has developed the F.A.C.E.R. 1.0 (integrating the Aglaris technology in an fully autonomous system) which is currently under validation at Aglaris’ headquarters at the Stevenage Bioscience Catalyst (UK) and its laboratory premises at Parque Tecnológico de Madrid (Spain).